World’s first dengue fever vaccine Dengvaxia cleared by Mexico for public use

The Mexican drug authorities have approved Sanofi Pastur’s first ever dengue vaccineDengvaxia, which promises to reduce the disease burden by 50 percent in five years among vulnerable populations.

About Dengvaxia :

• The Federal Commission for the Protection against Sanitary Risks (COFEPRIS) has approved Dengvaxia, tetravalent dengue vaccine, for the prevention of disease caused by all four dengue virus serotypes inpreadolescents, adolescents and adults, 9 to 45 years of age living in endemic areas.
• The approval from Mexican authorities, Sanofi is based on results from an extensive clinical development program involving over 40,000 people of different ages, geographic and epidemiological settings, and ethnic and socio-economic backgrounds living in 15 countries.

Keys : The World Health Organisation has called on endemic countries to reduce dengue mortality by 50% and morbidity by 25% by 2020.